Peregrion

Peregrion is a spin-off from TNO that offers advanced biomedical accelerator mass spectrometry (AMS) microtracer studies to accelerate early clinical development of new medicines. Their proprietary AMS-based platform enables highly sensitive detection of drug absorption, distribution, metabolism, and excretion in humans at very low radioactivity levels. This approach allows pharmaceutical companies to obtain critical human data earlier in the development process—often as early as Phase 1—while reducing or eliminating the need for animal radiolabeled ADME studies. The technology is already adopted by many top global pharma companies to de-risk pipelines and optimize dosing/formulation strategies[1][2][3][5].